Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2016	Mar. 03, 2017	Jun. 30, 2016
Document And Entity Information [Abstract]
Entity Registrant Name	Pulse Biosciences, Inc.
Entity Filer Category	Smaller Reporting Company
Entity Central Index Key	0001625101
Trading Symbol	plse
Amendment Flag	false
Document Type	10-K
Document Fiscal Period Focus	FY
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2016
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Common Stock, Shares Outstanding		14,136,220
Entity Public Float			$ 54,677,000

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 2,089	$ 3,606
Marketable investments	14,306
Prepaid expenses and other current assets	268	44
Deferred offering costs		347
Total current assets	16,663	3,997
Equipment, net of accumulated depreciation	317	329
Intangible assets, net of accumulated amortization	6,543	7,208
Goodwill	2,791	2,791
Total assets	26,314	14,325
Current liabilities:
Accounts payable	265	262
Accrued expenses	751	398
Total current liabilities	1,016	660
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; authorized - 5,000 shares; issued and outstanding - none
Common stock, $0.001 par value: authorized – 45,000 shares; issued and outstanding – 13,315 shares and 7,565 shares at September 30, 2016 and December 31, 2015, respectively	13	8
Additional paid-in-capital	37,898	16,745
Accumulated other comprehensive loss	(7)
Accumulated deficit	(12,606)	(3,088)
Total stockholders' equity	25,298	13,665
Total liabilities and stockholders' equity	$ 26,314	$ 14,325

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Consolidated Balance Sheets [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	45,000,000	45,000,000
Common stock, shares issued	13,315,000	7,565,000
Common stock, shares outstanding	13,315,000	7,565,000

Consolidated Statements Of Operations And Comprehensive Loss - USD ($) shares in Thousands	3 Months Ended								7 Months Ended	12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Consolidated Statements Of Operations And Comprehensive Loss [Abstract]
Revenue
Operating expenses:
General and administrative	$ 870,000	$ 893,000	$ 642,000	$ 528,000	$ 417,000	$ 408,000	$ 243,000	$ 156,000	43,000	2,933,000	1,224,000
Research and development	1,806,000	1,739,000	1,453,000	990,000	951,000	659,000	547,000	421,000	26,000	5,988,000	2,578,000
Amortization of intangible assets	167,000	166,000	166,000	166,000	167,000	167,000	166,000	166,000	111,000	665,000	666,000
Costs of business acquisitions									120,000
Total operating expenses	2,843,000	2,798,000	2,261,000	1,684,000	1,535,000	1,234,000	956,000	743,000	300,000	9,586,000	4,468,000
Other income:
Interest income	34,000	31,000	3,000							68,000
Total other income	34,000	31,000	3,000							68,000
Loss from operations, before income taxes	(2,809,000)	(2,767,000)	(2,258,000)	(1,684,000)	(1,535,000)	(1,234,000)	(956,000)	(743,000)	(300,000)	(9,518,000)	(4,468,000)
Income tax benefit					(518,000)	(483,000)	(357,000)	(299,000)	(23,000)		(1,657,000)
Net loss	(2,809,000)	(2,767,000)	(2,258,000)	(1,684,000)	(1,017,000)	(751,000)	(599,000)	(444,000)	(277,000)	(9,518,000)	(2,811,000)
Other comprehensive loss:
Unrealized loss on available-for-sale securities, net of tax	1,000	(8,000)								(7,000)
Comprehensive loss	$ (2,808,000)	$ (2,775,000)	$ (2,258,000)	$ (1,684,000)	$ (1,017,000)	$ (751,000)	$ (599,000)	$ (444,000)	$ (277,000)	$ (9,525,000)	$ (2,811,000)
Net loss per common share - basic and diluted	$ (0.21)	$ (0.21)	$ (0.23)	$ (0.22)	$ (0.13)	$ (0.10)	$ (0.08)	$ (0.06)	$ (0.11)	$ (0.86)	$ (0.37)
Weighted average shares used to compute net loss per common share	13,315	13,315	9,791	7,565	7,565	7,565	7,565	7,565	2,511	11,009	7,565

Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]	Total
Net loss for the period from May 19, 2014 (inception) through December 31, 2014				$ (2,811)	$ (2,811)
Balance at Dec. 31, 2014	$ 8	16,343		(277)	16,074
Balance, shares at Dec. 31, 2014	7,565
Stock-based compensation expense		402			402
Net loss				(2,811)	(2,811)
Balance at Dec. 31, 2015	$ 8	16,745		(3,088)	$ 13,665
Balance, shares at Dec. 31, 2015	7,565				7,565
Net loss for the period from May 19, 2014 (inception) through December 31, 2014				(9,518)	$ (9,518)
Issuance of common stock upon initial public offering, net of issuance costs	$ 5	20,283			20,288
Issuance of common stock upon initial public offering, net of issuance costs, shares	5,750
Stock-based compensation expense		870			870
Unrealized gain (loss) on available-for-sale securities, net of tax			(7)		(7)
Net loss				(9,518)	(9,518)
Balance at Dec. 31, 2016	$ 13	$ 37,898	$ (7)	$ (12,606)	$ 25,298
Balance, shares at Dec. 31, 2016	13,315				13,315

Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	7 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Net loss	$ (277)	$ (9,518)	$ (2,811)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of equipment	6	94	51
Amortization of intangible assets	111	665	666
Stock-based compensation		870	402
Net premium amortization on marketable investments		4
Change in deferred income taxes	(23)		(1,657)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	12	(135)	(12)
Deferred offering costs		(280)	(347)
Accounts payable	29	3	125
Accrued expenses	58	246	305
Deferred grant revenue	(17)		(39)
Net cash used in operating activities	(101)	(8,051)	(3,317)
Cash flows from investing activities:
Purchase of equipment	(46)	(64)	(86)
Cash acquired in connection with acquisition of businesses	1
Purchase of marketable investments		(19,067)
Maturities of marketable investments		4,750
Net cash used in investing activities	(45)	(14,381)	(86)
Cash flows from financing activities:
Common stock issued to founders	8
Net proceeds from private placement	7,147
Proceeds from issuance of common stock from initial public offering, net of issuance costs		20,915
Net cash provided by financing activities	7,155	20,915
Net increase (decrease) in cash	7,009	(1,517)	(3,403)
Cash and cash equivalents at beginning of period		3,606	7,009
Cash and cash equivalents at end of period	7,009	2,089	3,606
Supplemental disclosure of noncash investing and financing activities:
Reclassification of deferred offering costs to additional paid-in capital upon initial public offering		627
Fair value of common stock issued in connection with license agreement	3,785
Fair value of common stock issued in connection with acquisition of businesses	$ 5,411
Equipment purchased in accrued expenses		$ 18	$ 104

Organization and Business Operations	12 Months Ended
Organization and Business Operations	Dec. 31, 2016
Organization and Business Operations [Abstract]
Organization and Business Operations	1. Organization and Description of Business Business and Basis of Presentation Pulse Biosciences, Inc., incorporated in Nevada on May 19, 2014, is a clinical-stage medical technologies company developing commercial clinical applications for its proprietary Nano-Pulse Stimulation (“NPS”) technology. NPS is a novel patented technology which leverages nano-second duration energy pulses that have demonstrated effective local tumor control and the initiation of an adaptive immune response in pre-clinical studies. The Company is pursuing a number of clinical applications for NPS, including human oncology, dermatology, aesthetics and other minimally invasive applications where NPS is believed to provide greater benefits compared to current therapies and treatments. Pulse Biosciences, Inc. is referred to individually as “Pulse” and collectively with its wholly-owned subsidiaries as described below as the “Company” or “Pulse Biosciences, Inc.” The Company’s corporate office and research facility are located in Burlingame, California. The Company’s activities are subject to significant risks and uncertainties, including the need for additional capital. The Company has not yet commenced any revenue-generating operations, does not have any cash flows from operations, and will need to raise additional capital to finance its operations. However, there can be no assurances that the Company will be able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund its operating requirements. Initial Public Offering On May 13, 2016, the Company’s registration statement on Form S-1 (File No. 333-208694), as amended (the “Registration Statement”), relating to its initial public offering (“IPO”) was declared effective by the Securities and Exchange Commission (“SEC”) and closed on May 23, 2016, whereby the Company sold 5,000,000 shares of common stock at $4.00 per share. The shares began trading on the NASDAQ Capital Market under the trading symbol “PLSE” on May 18, 2016. On June 21, 2016, the underwriters exercised their overallotment option to purchase an additional 749,846 shares of the Company’s common stock at $4.00 per share. The Company received net proceeds of approximately $20.3 million from the IPO, including proceeds from the exercise of the overallotment option granted to the underwriters, net of underwriting discounts and commissions and other offering costs.

Summary Of Significant Accounting Policies

12 Months Ended

Dec. 31, 2016

Summary Of Significant Accounting Policies [Abstract]

Summary Of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Principles of Consolidation

The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and include the financial statements of Pulse and its wholly-owned subsidiaries, BioElectroMed Corp. (“BEM”) and NanoBlate Corp. (“NB”), since their date of acquisition on November 6, 2014. ThelioPulse, Inc. (“TPI”), which was acquired on November 6, 2014, was merged into Pulse subsequent to its acquisition and ceased to exist as a separate entity. Intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual amounts could differ from those estimates.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and investments. The Company places its cash equivalents and investments with high credit quality financial institutions and, by policy, limits the amounts invested with any one financial institution or issuer. Deposits held with banks may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses since inception.

Fair Value of Financial Instruments

The Company believes the carrying amounts of its financial instruments, including cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses, approximate fair value due to the short-term nature of such instruments.

Cash, Cash Equivalents and Marketable Investments

The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The Company has designated all marketable investments as available-for-sale and therefore, such marketable investments are reported at fair value, with unrealized gains and losses recognized in accumulated other comprehensive income (loss) (“OCI”) in stockholders’ equity. The cost of marketable securities is adjusted for the amortization of premiums and discounts to expected maturity. Premium and discount amortization is included in other income, net. Realized gains and losses, as well as interest income, on available-for-sale securities are also included in other income, net. The Company includes all of its available-for-sale securities in current assets.

All of the Company’s marketable investments are subject to a periodic impairment review. The Company recognizes an impairment charge when a decline in the fair value of its marketable investments below the cost basis is judged to be other-than-temporary. Factors considered in determining whether a loss is temporary include the length of time and extent to which the marketable investments fair value has been less than the cost basis, the financial condition and near-term prospects of the investee, extent of the loss related to credit of the issuer, the expected cash flows from the security, the Company’s intent to sell the security and whether or not the Company will be required to sell the security before the recovery of its amortized cost. During the year ended December 31 2016, the Company did not recognize any impairment charges on its investments as it is more likely than not that the Company will recover their amortized cost basis upon sale or maturity. The Company did not hold investment securities at any time during the prior year.

Deferred and Capitalized Offering Costs

Costs incurred in connection with ongoing equity financing activities, consisting primarily of legal, accounting and other professional fees, are deferred until the related financing is either completed or abandoned. Costs related to completed equity financings are charged directly to additional paid-in capital. Costs related to abandoned financings are charged to operations.

Equipment

Equipment is recorded at cost and depreciated on a straight-line basis over their estimated useful lives, ranging from three to five years.

Intangible Assets

The Company’s intangible assets consist of acquired patents and licenses, which are being amortized over their estimated useful lives of twelve years.

Long-Lived Assets

The Company reviews long-lived assets, consisting of equipment and intangible assets, for impairment during each fiscal year or when events or changes in circumstances indicate the carrying value of these assets may exceed their current fair values. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the assets. Assets to be disposed of are separately presented in the consolidated balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated. The Company has not historically recorded any impairment to its long-lived assets. In the future, if events or market conditions affect the estimated fair value to the extent that a long-lived asset is impaired, the Company will adjust the carrying value of these long-lived assets in the period in which the impairment occurs. For the years ended December 31, 2016, 2015 and the period from May 19, 2014 (inception) through December 31, 2014, the Company had not deemed any long-lived assets as impaired, and was not aware of the existence of any indicators of impairment at such dates.

Goodwill

The Company records goodwill when the consideration paid in a business acquisition exceeds the fair value of the net tangible assets and the identified intangible assets acquired. The Company reviews goodwill for impairment at least annually or whenever changes in circumstances indicate that the carrying value of the goodwill may not be recoverable. For the years ended December 31, 2016, 2015 and the period from May 19, 2014 (inception) through December 31, 2014, the Company had not deemed the value of goodwill as impaired, and was not aware of the existence of any indicators of impairment at such dates.

Stock-Based Compensation

The Company periodically issues stock options to officers, directors, employees and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date.

Stock-based payments to officers, directors and employees, including grants of employee stock options, are recognized in the financial statements based on their grant date fair values. Stock option grants, which are generally time vested, are measured at the grant date fair value and charged to operations on a straight-line basis over the vesting period. The fair value of stock options is determined utilizing the Black-Scholes option-pricing model, which is affected by several variables, including the risk-free interest rate, the expected dividend yield, the life of the equity award, the exercise price of the stock option as compared to the fair value of the common stock on the grant date, and the estimated volatility of the common stock over the term of the equity award.

The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The Company estimates volatility based on the average historical volatilities of comparable public companies in a similar industry. The expected dividend yield is based on the current yield at the grant date; the Company has never declared or paid dividends and has no plans to do so for the foreseeable future. As permitted by Staff Accounting Bulletin No. 107, due to the Company’s lack of history and option activity, management utilizes the simplified method to estimate the expected term of options at the date of grant. Prior to the Company’s IPO, the fair value of common stock was determined by reference to either recent or anticipated cash transactions involving the sale of the Company’s common stock.

Stock options issued to non-employees as compensation for services provided to the Company are accounted for based upon the estimated fair value of the stock option. Management utilizes the Black-Scholes option-pricing model to determine the fair value of the stock options issued by the Company. The Company recognizes this expense over the period in which the services are provided.

The Company recognizes the fair value of stock-based compensation costs in general and administrative costs and in research and development costs, as appropriate, in the Company’s consolidated statements of operations. The Company issues new shares to satisfy stock option exercises.

Research Grants

Research grants are generally funded and paid through governmental, institutional, educational or research organizations. Grants received from agencies of the federal government are subject to federal regulation as to how the Company conducts its research activities, and the Company is required to comply with the respective research agreement terms relating to those grants. Amounts received under research grants are nonrefundable, regardless of the success of the underlying research project, to the extent that such amounts are expended in accordance with the approved grant project. The Company is permitted to draw down the research grants after incurring the related expenses. Amounts received under research grants are offset against the related research and development costs in the Company’s consolidated statement of operations as the costs are incurred.

Research and Development Costs

Research and development costs consist primarily of compensation costs, fees paid to consultants and outside service providers and organizations (including research institutes at universities), development prototypes, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s product candidates. Research and development costs incurred by the Company are expensed as incurred, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different expensing schedule is more appropriate.

Patent Costs

The Company is the owner of numerous domestic and foreign patents. Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and any related patent applications, patent costs not related to acquired patents, including patent-related legal fees, filing fees and other costs, including internally generated costs, are expensed as incurred. During the years ended December 31, 2016 and 2015 patent costs totaled $0.5 million and $0.4 million, respectively. During the period from May 19, 2014 (inception) through December 31, 2014, patent costs were $26,000. Patent costs are included in research and development costs in the consolidated statements of operations and comprehensive loss.

Income Taxes

The Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities.

The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company determines that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made.

The Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company’s net operating losses have yet to be utilized, previous tax years remain open to examination by federal authorities and other jurisdictions in which the Company currently operates or has operated in the past. The Company is not currently under examination by any tax authority.

The Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by U.S. GAAP. The tax effects of a position are recognized only if it is “more-likely-than-not” to be sustained by the taxing authority as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits of the position are recognized. At December 31, 2016 and 2015, the Company had not recorded any liability for uncertain tax positions. The Company includes interest and penalties related to uncertain tax positions as a component of income tax expense.

Comprehensive Loss

Comprehensive loss consists of net loss and unrealized gains or losses on available-for-sale investments. The Company displays comprehensive loss and its components as part of the consolidated statements of operations and comprehensive loss.

Net Loss per Share

The Company’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period. For purposes of this calculation, options to purchase common stock and common stock warrants are considered common stock equivalents. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted net loss per share.

Basic and diluted net loss per common share is the same for all periods presented because all warrants and stock options outstanding are anti-dilutive.

The following outstanding stock options and warrants to purchase common stock were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect:



					May 19, 2014
					(inception)
	Years Ended				through
	December 31,				December 31,
	2016		2015		2014
Common stock warrants		874,610		299,625		299,625
Common stock options		1,229,355		875,221		—
Total		2,103,965		1,174,846		299,625

Segment and Geographical Information

The Company operates and manages its business as one reportable and operating segment. The Company’s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. All of the Company’s long-lived assets are based in the United States.

Recently Adopted Standards

In August 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Updates (“ASU”) No. 2014-15, Presentation of Financial Statements – Going Concern Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern, which requires management to evaluate whether there are conditions or events that raise substantial doubt about an entity’s ability to continue as a going concern and to provide disclosures when certain criteria are met. The guidance is effective for annual periods beginning after December 15, 2016 and interim reporting periods starting in the first quarter of 2017. The Company adopted this standard as of December 31, 2016.

Recent Accounting Pronouncements

During May 2014, the Financial Accounting Standards Board (“FASB”) issued (“ASU”) No. 2014-09, Revenue from Contracts with Customers. This updated standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective and permits the use of either the retrospective or cumulative effect transition method. In August 2015, the FASB issued an update to defer the effective date of this update by one year. This updated standard becomes effective for the Company in the first quarter of fiscal year 2018, but allows the Company to adopt the standard one year earlier if it so chooses. In March 2016, the FASB issued updates to this guidance to clarify the implementation guidance on principal versus agent considerations. In April 2016, the FASB issued guidance to clarify aspects related to identifying performance obligations and the licensing implementation guidance. In May 2016, the FASB issued guidance to clarify the implementation on narrow scope improvements and practical expedients. The Company is currently evaluating the impact of adopting these standards.

During February 2016, the FASB issued ASU No. 2016-02, Leases, which amends the existing accounting standards for leases. The new standard requires lessees to record a right-of-use asset and a corresponding lease liability on the balance sheet (with the exception of short-term leases). For lessees, leases will continue to be classified as either operating or financing in the income statement. This ASU becomes effective for the Company in the first quarter of fiscal year 2019 and early adoption is permitted. This ASU is required to be applied with a modified retrospective approach and requires application of the new standard at the beginning of the earliest comparative period presented. The Company generally does not finance purchases of equipment or other capital, but does lease its facilities. While the Company is continuing to assess all potential impacts of this standard, it expects that most of its lease commitments will be subject to the updated standard and recognized as lease liabilities and right-of-use assets upon adoption.

During March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-based Payment Accounting. This ASU simplifies the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. This ASU requires that excess tax benefits and deficiencies be recognized as income tax benefit or expense in the income statement. The Company currently plans to implement this ASU as required in the first quarter of fiscal year 2017. The Company does not expect the adoption of this ASU to have a significant impact on its financial position.

During June 2016, the FASB issued ASU 2016-13, Financial Instruments — Measurement of Credit Losses on Financial Instruments, which requires measurement and recognition of expected credit losses for financial assets held. ASU 2016-13 is effective for the Company beginning January 1, 2020. The Company is currently evaluating the impact of adopting this standard.

During January 2017, the FASB issued ASU 2017-04, Intangibles — Goodwill and Other (Topic 350): Simplifying the Accounting for Goodwill Impairment, which simplifies the accounting for goodwill impairment. This ASU removes Step 2 of the goodwill impairment test, which requires hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The new guidance also requires disclosure of the amount of goodwill at reporting units with zero or negative carrying amounts. ASU 2017-04 is effective for the Company beginning January 1, 2020. Early adoption is permitted for any impairment tests performed after January 1, 2017. The Company is currently evaluating the impact of adopting this standard.

Fair Value Of Financial Instruments

12 Months Ended

Dec. 31, 2016

Fair Value Of Financial Instruments [Abstract]

Fair Value Of Financial Instruments

3. Fair Value of Financial Instruments

The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below.

Level 1 - Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives.

Level 2 - Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges.

Level 3 - Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded, non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models.

The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end.

The Company classifies its investments in money market funds within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. The Company classifies its Level 2 instruments based on market pricing and other observable inputs. The Company did not classify any of its investments within Level 3 of the fair value hierarchy.

The following table sets forth the fair value of the Company’s financial assets measured on a recurring basis as of December 31, 2016 (in thousands):



		December 31, 2016
Assets	Classification		Level 1		Level 2		Level 3		Total
Money market funds	Cash and cash equivalents	$	1,726	$	—	$	—	$	1,726
Corporate bonds	Investments		—		13,289		—		13,289
Asset-backed security	Investments		—		1,017		—		1,017
Total assets measured at fair value		$	1,726	$	14,306	$	—	$	16,032

The Company did not have any financial assets measured on a recurring basis as of December 31, 2015. The Company did not have any financial liabilities measured on a recurring basis as of December 31, 2016 and 2015.

During the year ended December 31, 2016, the Company did not record any impairment charges related to its marketable investments. There were no transfers between Level 1, Level 2 or Level 3 assets reported at fair value on a recurring basis and the valuation techniques used did not change compared to the Company’s established practice.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Equipment

12 Months Ended

Dec. 31, 2016

Equipment [Abstract]

Equipment

4. Equipment

Equipment consisted of the following (in thousands):



	December 31,
	2016		2015
Laboratory equipment	$	425	$	356
Software		20		10
Furniture, fixtures and equipment		17		20
		462		386
Less: Accumulated depreciation		(145)		(57)
	$	317	$	329

Depreciation expense for the years ended December 31, 2016, 2015 and the period from May 19, 2014 (inception) to December 31, 2014 was $94,000, $51,000 and $6,000, respectively.

Intangible Assets

12 Months Ended

Dec. 31, 2016

Intangible Assets [Abstract]

Intangible Assets

5. Intangible Assets

Intangible assets consisted of the following (in thousands):



	December 31,
	2016		2015
Acquired patents and licenses	$	7,985	$	7,985
Less: Accumulated amortization		(1,442)		(777)
	$	6,543	$	7,208

A schedule of the amortization of intangible assets for the five years ending December 31, 2017 through 2021 and thereafter is as follows (in thousands):



Year Ending December 31:
2017	$	665
2018		666
2019		665
2020		666
2021		665
Thereafter		3,216
	$	6,543

Accrued Expenses

12 Months Ended

Dec. 31, 2016

Accrued Expenses [Abstract]

Accrued Expenses

6. Accrued Expenses

Accrued expenses consisted of the following (in thousands):



	December 31,
	2016		2015
Professional fees	$	285	$	84
Compensation expense		261		34
Other		205		40
Offering costs		—		240
	$	751	$	398

Stockholders' Equity And Stock-Based Compensation

12 Months Ended

Dec. 31, 2016

Stockholders' Equity And Stock-Based Compensation [Abstract]

Stockholders' Equity And Stock-Based Compensation

7. Stockholders’ Equity and Stock-Based Compensation

Preferred Stock

The Company has authorized a total of 5,000,000 shares of preferred stock, par value $0.001 per share, none of which were outstanding at December 31, 2016 and 2015. The Company’s Board of Directors has the authority to issue preferred stock and to determine the rights, preferences, privileges, and restrictions, including voting rights, without any further vote or action by the Company’s stockholders.

Common Stock

The Company has authorized a total of 45,000,000 shares of common stock, par value $0.001 per share.

In conjunction with the incorporation of the Company, 1,125,000 shares of common stock were issued to its founding stockholders, which consisted of MDB Capital Group, LLC and its affiliated persons, for cash consideration of $8,000.

During November 2014, the Company sold 2,996,253 shares of common stock in a private placement to accredited investors for $2.67 per share, resulting in gross cash proceeds of $8.0 million. Direct costs of the private placement consisted of a 10% placement agent fee to MDB Capital Group, LLC and its designees, of $0.8 million and related legal fees and reimbursable expenses of $54,000. In conjunction with this private placement, the Company issued warrants to MDB Capital Group, LLC and its designees for a consideration of $1,000. The placement agent warrants had a fair value of $0.6 million, calculated pursuant to the Black-Scholes option-pricing model, as described below. Issuance costs of the private placement, net of the consideration received from MDB Capital Group, LLC of $1,000, aggregated $0.9 million and were charged directly to additional paid-in capital.

During November 2014, the Company issued an aggregate of 3,444,198 shares of common stock valued at $9.2 million to acquire businesses and intellectual property license rights.

During May 2016, the Company completed an IPO whereby it sold 5,749,846 shares of the Company’s common stock at $4.00 as described in Note 1.

Common Stock Warrants

During the year ended December 31, 2016, in connection with the closing of the Company’s initial public offering, the Company issued warrants as compensation to the underwriters of its initial public offering to purchase a total 574,985 shares of is common stock at a price of $5.00 per share. The warrants became exercisable 180 days after issuance and are exercisable for a period of five years. These warrants were valued pursuant to the Black-Scholes option-pricing model at $1.4 million, based on the following assumptions: fair value of common stock – $4.12 to $4.27 per share; risk free interest rate: 1.22% – 1.38%; expected volatility – 80%; expected dividend yield – 0%; and expected term – 5 years.

In conjunction with the private placement of common stock during November 2014 at $2.67 per share, the Company issued warrants to the placement agent to purchase 299,625 shares of common stock, exercisable at issuance for a period of seven years at $2.67 per share. The placement agent warrants have standard anti-dilution protections and cashless exercise rights. The placement agent warrants have piggy-back registration rights commencing on the date that the Company became a reporting company under the Securities Exchange Act of 1934, as amended, and for a period of seven years thereafter, and a one-time demand registration right commencing six months after the date that the Company became a reporting company under the Securities Exchange Act of 1934, as amended, and for a period of 54 months thereafter.

A summary of warrant activity for the year ended December 31, 2016 is presented below:



				Weighted
				Average
		Weighted		Remaining
	Number of	Average		Contractual
	Shares	Exercise Price		Life (in Years)
Warrants outstanding at December 31, 2015	299,625	$	2.67	5.85
Issued	574,985		5.00
Exercised	—		—
Expired/terminated	—		—
Warrants outstanding and exercisable at December 31, 2016	874,610	$	4.20	4.53

The intrinsic value of exercisable in-the-money stock warrants was approximately $2.0 million as of December 31, 2016.

Stock Options

During August 2015, the Company adopted the 2015 Stock Incentive Plan (the “2015 Plan”) and reserved 1,134,818 shares of common stock for issuance under the 2015 Plan, including stock options and restricted or performance stock awards. The 2015 Plan is administered by the Compensation Committee of the Company’s Board of Directors. Eligible participants in the 2015 Plan include the Company’s employees, officers and directors, and any person who has a business relationship with the Company. Options issued under the 2015 Plan may have a term of up to ten years and may have variable vesting provisions. New hire grants generally vest 25% upon the first anniversary of the grant and 1/12 quarterly thereafter, over the subsequent twelve quarters. Grants issued to existing employees generally vest quarterly over four years.

During the year ended December 31, 2015, prior to the adoption of the 2015 Plan, all of the stock options granted to directors were at an exercise price of $2.67 per share, the same price as the common shares sold in the November 2014 private placement. Pursuant to an employment agreement with Darrin Uecker, the Company’s President and Chief Executive Officer (the “Executive”), the Company agreed to issue to the Executive, upon consummation of the proposed IPO, an additional stock option equal to 3% of the Company’s fully diluted shares of common stock outstanding after taking into account the shares to be issued in the IPO exercisable at the IPO per share price. On October 5, 2016, the Executive offered, and the Company accepted, to forgo receipt of such grant until such time the Company’s shareholders approve a new equity incentive plan or an increase in the number of shares available under the existing plan. In exchange for the Executive’s forgoing receipt of the post-IPO option grant, the Company agreed to amend the Executive’s employment agreement (the “Amendment”) so that the Executive will receive (i) an option grant to purchase 187,286 shares of the Company’s common stock, which is a number of shares equal to the number of shares he would have been entitled to receive upon completion of the IPO, and (ii) a restricted stock grant equal in value to (A) the difference between the exercise price previously agreed to for the post-IPO option grant, which was $4.00 per share, and the exercise price on the date of the deferral grant, multiplied by (B) 187,286. In the event of a change of control that precedes the aforementioned option grant while the Executive is still an employee of the Company, the Executive would be entitled to receive a cash bonus equal to the consideration the Executive would have received as a holder of 187,286 vested options to purchase the Company’s common stock at an exercise price of $4.00 per share.

A summary of stock option activity for the year ended December 31, 2016 is presented below:



				Weighted
		Weighted		Average
		Average		Remaining
	Number of	Exercise		Contractual
	Shares	Price		Life (in Years)
Stock options outstanding at December 31, 2015	875,221	$	3.51	7.8
Issued	405,132		4.44
Exercised	—		—
Expired/terminated	(50,998)		3.57
Stock options outstanding at December 31, 2016	1,229,355	$	3.82
Vested and expected to vest at December 31, 2016	1,229,355	$	3.82	7.6
Stock options exercisable at December 31, 2016	354,855	$	3.34	6.0

The exercise prices of stock options outstanding and exercisable are as follows at December 31, 2016:



Options Outstanding				Options Exercisable
		Weighted average
	Number	remaining contractual	Weighted average	Number	Weighted average
Exercise Price	outstanding	life (in years)	exercise price	vested	exercise price
$2.67	302,620	3.3	$ 2.67	176,528	$ 2.67
$4.00 - $4.28	692,335	8.9	4.02	178,327	4.00
$4.67 - $4.68	234,400	9.6	4.68	—	-
	1,229,355	7.6	$ 3.82	354,855	$ 3.34

The intrinsic value of exercisable in-the-money stock options at December 31, 2016 was approximately $1.1 million.

The fair value of option awards was estimated using the Black-Scholes option-pricing model utilizing the following assumptions:



					May 19, 2014
					(inception)
	Years Ended				through
	December 31,				December 31,
	2016		2015		2014
Expected term in years		6.08		3.5 - 6.25		—
Expected volatility		80%		89% - 90%		—
Risk-free interest rate		1.16%-1.45%		0.88% - 1.89%		—
Dividend yield		—		—		—

The fair value of the stock options granted during the years ended December 31, 2016 and 2015, calculated pursuant to the Black-Scholes option-pricing model, was $1.2 million and $3.1 million, respectively.

Total stock-based compensation expense consisted of the following (in thousands):



					May 19, 2014
					(inception)
	Years Ended				through
	December 31,				December 31,
	2016		2015		2014
General and administrative	$	674	$	397	$	—
Research and development		196		5		—
Total stock-based compensation expense	$	870	$	402	$	—

At December 31, 2016, there was $2.4 million of unrecognized compensation cost related to unvested stock-based compensation arrangements, which is expected to be recognized over a weighted average period of 2.84 years.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

Research Grants And Agreements	12 Months Ended
Research Grants And Agreements	Dec. 31, 2016
Research Grants And Agreements [Abstract]
Research Grants And Agreements	8. Research Grants and Agreements Research Grants The Company’s subsidiary, BEM, was acquired by Pulse in November 2014. BEM had received grants from the National Cancer Institute of the National Institutes of Health (the “NIH”), including grants from the NIH Small Business Innovation Research (“SBIR”) Program, to conduct research and develop devices that will provide health benefits utilizing bioelectric technology. At the time of the acquisition, BEM had an active research grant under the SBIR Program for a project entitled “EndoPulse System for Endoscopic Ultrasound-Guided Therapy of Pancreatic Carcinoma.” This research project was completed during the year ended December 31, 2015. During the period from May 19, 2014 (inception) through December 31, 2014 and for the year ended December 31, 2015, the Company received research grant funding of $0.2 million and $0.3 million, respectively. The Company has not subsequently pursued additional grants. Sponsored Research Agreement The Company sponsors research activities performed by ODURF’s Frank Reidy Center. ODURF is compensated by the Company for its conduct of each study in accordance with the budget and payment terms set forth in the applicable task order. During the years ended December 31, 2016 and 2015, the Company agreed to sponsor $1.0 million and $1.2 million, respectively, during the subsequent 12-month period. The principal investigator may transfer funds with the budget as needed without the Company’s approval so long as the obligations of ODURF under the task order and statement of work remain unchanged and unimpaired. During the year ended December 31, 2016 and 2015, the Company incurred $0.9 million and $1.0 million, respectively, of costs pursuant to various task orders.

- Definition

The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.

+ References + Details

Income Taxes

12 Months Ended

Dec. 31, 2016

Income Taxes [Abstract]

Income Taxes

9. Income Taxes

The income tax provision for the year ended December 31, 2016 was $0. The income tax provision for the year ended December 31, 2015 and the period from May 19, 2014 (inception) through December 31, 2014 was a benefit of $1.7 million and $23,000, respectively. The prior years’ tax benefits resulted from the realization of deferred tax assets related principally to the Company’s net operating loss for the year ended December 31, 2015, offset by deferred tax liability created based upon the difference in the value for book and tax purposes of certain acquired technology assets, which are considered temporary income tax differences under purchase accounting. A full valuation allowance is provided against the Company’s remaining deferred tax assets.

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets at December 31, 2016 and 2015 are summarized below (in thousands):



	December 31,
	2016		2015
Technology	$	(1,449)	$	(1,630)
Temporary differences		312		103
Credits		639		198
Net operating loss carryforwards		5,121		1,590
Total deferred tax assets		4,623		261
Valuation allowance		(4,623)		(261)
Net deferred tax assets	$	—	$	—

In assessing the potential realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the Company attaining future taxable income during the periods in which those temporary differences become deductible. At December 31, 2016 and 2015, management was unable to determine that it was more likely than not that the Company’s deferred tax assets will be realized, and has therefore recorded an appropriate valuation allowance against deferred tax assets at such dates.

The Company’s effective tax rate is different from the federal statutory tax rate of 35% due primarily to net losses that receive no tax benefit as a result of a valuation allowance recorded for such losses.

Presented below is the reconcilement of the difference between the tax rate computed by applying the U.S. federal statutory tax rate and the effective tax rate for the years ended December 31, 2016, 2015 and for the period from May 19, 2014 through December 31, 2014:



					May 19, 2014
					(inception)
	Years Ended				through
	December 31,				December 31,
	2016		2015		2014
U.S. federal statutory tax rate	(35.0)	%	(35.0)	%	(35.0)	%
Valuation allowance	42.0	%	4.0	%	16.0	%
Permanent differences	2.0	%	1.0	%	15.0	%
State tax benefit and other	(9.0)	%	(7.0)	%	(4.0)	%
Effective tax rate	—	%	(37.0)	%	(8.0)	%

At December 31, 2016, the Company had federal and California state net operating loss carryforwards of approximately $11.7 million and $11.5 million, respectively. The federal and state net operating loss carryforwards will begin to expire after 2032. At December 31, 2016, the Company had approximately $0.4 million and $0.4 million of federal and California R&D credits, respectively. The federal R&D credits begin to expire after 2035 and the California R&D credits have an indefinite carryforward period.

These net operating loss carryforward and research and development credit amounts have full valuation allowances against them due to the remoteness of their expected utilization. While the Company has not performed a formal analysis of the availability of these operating loss carryforwards at December 31, 2016 under Internal Revenue Code Sections 382 and 383, management expects that the Company’s ability to use its net operating loss carryforwards may be limited in future periods.

The Company’s activity related to unrecognized tax benefits are summarized below (in thousands):


	December 31,
	2016		2015
Balance, January 1, 2016	$	66	$	—
Gross increases - tax positions in prior periods		—		—
Gross decreases - tax positions in prior periods		—		—
Gross increases - tax position in current period		147		66
Settlements		—		—
Lapses in statutes of limitations		—		—
Balance, December 31, 2016	$	213	$	66

Although it is reasonably possible that certain unrecognized tax benefits may increase or decrease within the next twelve months due to tax examination changes, settlement activities, expirations of statute of limitations, or the impact on recognition and measurement considerations related to the results of published tax cases or other similar activities, the Company does not anticipate any significant changes to unrecognized tax benefits over the next twelve months. During the years ended December 31, 2016, 2015 and the period from May 19, 2014 to December 31, 2014, no interest or penalties were required to be recognized related to unrecognized tax benefits. Although the Company is not under examination, the tax years for 2014 and forward are subject to examination by United States tax authorities.

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions	10. Related Party Transactions MDB Capital Group, LLC (“MDB”) provided investment banking, executive recruiting and intellectual property management services to the Company. Furthermore, provisions of the Company’s investment banking agreement with MDB survive the June 2016 termination of the agreement for a period of two years and MDB retains significant rights under the 2016 IPO underwriting agreement with respect to the Company’s future financing alternatives for up to five years. The Company’s Chairman, Robert Levande, is a Senior Managing Director of MDB. In connection with the Company’s 2016 IPO (Note 1), the underwriting syndicate led by MDB received $1.8 million in underwriting discounts, $0.2 million in unaccountable expense reimbursements and warrants valued in the aggregate of $1.4 million. In addition, during the period from May 19, 2014 (inception) to December 31, 2014 (Note 7), MDB received cash placement agent fees of $0.8 million and the Company issued warrants to purchase 299,625 shares of common stock for a consideration of $1,000, exercisable for seven years at $2.67 per share, to MDB Capital Group, LLC and its designees. During the year ended December 31, 2016, the Company incurred non-financing related expenses charged by MDB of $100,000 for services rendered with respect to intellectual property related services. Similarly, during the year ended December 31, 2015, the Company incurred expenses charged by MDB comprised of: $49,000 for services rendered with respect to executive search activities related to the hiring of the Company’s Chief Executive Officer and the appointment of one director, $42,000 for offering related expenses and $26,000 for intellectual property related services. Gary Schuman, the Chief Financial Officer of MDB, was also the acting Chief Financial Officer of the Company and was compensated at a monthly rate of $4,000 from November 1, 2014 to December 31, 2015, reflecting an aggregate charge to general and administrative expenses of $48,000 and $8,000 for the year ended December 31, 2015 and the period from May 19, 2014 (inception) through December 31, 2014, respectively. At December 31, 2016, accounts payable and accrued expenses did not include any amounts payable to MDB. At December 31, 2015, included in accounts payable and accrued expenses is an amount of $58,000 payable to MDB for their expenses incurred relating to the Company’s planned IPO, which were recorded as deferred offering costs, and patent related services.

Commitments And Contingencies	12 Months Ended
Commitments And Contingencies	Dec. 31, 2016
Commitments And Contingencies [Abstract]
Commitments And Contingencies	11. Commitments and Contingencies Operating Leases The Company leases its corporate offices and research facilities in Burlingame, California, under an operating lease expiring March 31, 2017 at a monthly cost of approximately $19,000. In January 2017, the Company entered into a new lease agreement for premises consisting of approximately fifteen thousand six hundred ninety-seven (15,697) rentable square feet located in Hayward, California. See Note 14. During the years ended December 31, 2016, 2015 and the period from May 19, 2014 (inception) through December 31, 2014, rent expense, including common area maintenance charges, was $0.2 million, $0.2 million and $19,000, respectively.

Employee Benefit Plans	12 Months Ended
Employee Benefit Plans	Dec. 31, 2016
Employee Benefit Plans [Abstract]
Employee Benefit Plans	12. Employee Benefit Plans The Company sponsors a defined contribution plan under which it may make discretionary contributions. The Company did not make any employer matching contributions to this plan during the years ended December 31, 2016, 2015 or the period from May 19, 2014 (inception) through December 31, 2014.

Selected Quarterly Financial Data

12 Months Ended

Dec. 31, 2016

Selected Quarterly Financial Data [Abstract]

Selected Quarterly Financial Data

13. Selected Quarterly Financial Data (Unaudited)

The following table provides the selected quarterly financial data for the years ended December 31, 2016 and 2015 (in thousands, except per share data):


	Quarter Ended
	2016								2015
	December 31,		September 30,		June 30,		March 31,		December 31,		September 30,		June 30,		March 31,
Revenue	$	—	$	—	$	—	$	—	$	—	$	—	$	—	$	—
Operating expenses:
General and administrative		870		893		642		528		417		408		243		156
Research and development		1,806		1,739		1,453		990		951		659		547		421
Amortization of intangible assets		167		166		166		166		167		167		166		166
Total operating expenses		2,843		2,798		2,261		1,684		1,535		1,234		956		743
Other income:
Interest income		34		31		3		—		—		—		—		—
Total other income		34		31		3		—		—		—		—		—
Loss from operations, before income taxes		(2,809)		(2,767)		(2,258)		(1,684)		(1,535)		(1,234)		(956)		(743)
Income tax benefit		—		—		—		—		(518)		(483)		(357)		(299)
Net loss		(2,809)		(2,767)		(2,258)		(1,684)		(1,017)		(751)		(599)		(444)
Other comprehensive loss:
Unrealized gain (loss) on available-for-sale securities, net of tax:		1		(8)		—		—		—		—		—		—
Comprehensive loss	$	(2,808)	$	(2,775)	$	(2,258)	$	(1,684)	$	(1,017)	$	(751)	$	(599)	$	(444)
Net loss per share
Basic and diluted net loss per share	$	(0.21)	$	(0.21)	$	(0.23)	$	(0.22)	$	(0.13)	$	(0.10)	$	(0.08)	$	(0.06)
Weighted average shares used to compute net loss per common share — basic and diluted		13,315		13,315		9,791		7,565		7,565		7,565		7,565		7,565

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events Lease Agreement In January 2017, the Company entered into a new lease agreement (the “Lease”) for premises consisting of approximately fifteen thousand six hundred ninety-seven (15,697) rentable square feet located in Hayward, California (the “Premises”). The Premises will be used for the Company’s corporate headquarters and principal operating facility. The term of the Lease is sixty-two (62) months, commencing on the date that is the earlier of (i) the date upon which the Company commences business in the Premises or (ii) the date upon which the Premises is “Ready for Occupancy” as defined in the Lease. Base monthly rent shall be abated for the first two (2) months of the Lease term and thereafter will be $42,400 per month during the first year of the Lease term, with specified annual increases thereafter until reaching approximately $50,300 per month during the last two (2) months of the Lease term. The Company is required to pay a refundable security deposit of approximately $101,000. The Landlord is obligated to provide the Company with improvement allowances in the amount of approximately $135.00 per rentable square foot of the Premises, which may be applied towards the costs of construction of the initial improvements in the Premises. The Company will be responsible for any such improvement costs in excess of the foregoing allowances. The Company is required to reimburse Landlord for certain expenses during the Lease term. The Company has the right to extend the Lease term by five (5) years upon written notice not more than twelve (12) months nor less than nine (9) months prior to the expiration of the original Lease term, with monthly payments equal to the “Fair Rental Value” as defined in the Lease. The Company has also reserved the right to terminate the Lease if the Landlord is unable to deliver the facility to the Company by December 1, 2017. Assuming the Landlord delivers the facility to us by December 1, 2017, as of December 31, 2016, the lease obligations for less than one year, one to three years, three to five years and more than five years is approximately $0.3 million, $1.1 million, $1.1 million and $0.3 million, respectively. Private Placement On February 7, 2017, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with Robert W. Duggan and Maky Zanganeh (the “Investors”), pursuant to which the Company, in a private placement, agreed to issue and sell to the Investors an aggregate of 819,673 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a price per share of $6.10 (the “Shares”), for gross proceeds of approximately $5 million (the “Private Placement”). In connection with the Private Placement, the Company has granted certain registration rights to the Investors, pursuant to which, among other things, the Company will prepare and file with the Securities and Exchange Commission a registration statement to register for resale the Shares on or prior to July 31, 2017.

Summary Of Significant Accounting Policies (Policies)	12 Months Ended
Summary Of Significant Accounting Policies (Policies)	Dec. 31, 2016
Summary Of Significant Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and include the financial statements of Pulse and its wholly-owned subsidiaries, BioElectroMed Corp. (“BEM”) and NanoBlate Corp. (“NB”), since their date of acquisition on November 6, 2014. ThelioPulse, Inc. (“TPI”), which was acquired on November 6, 2014, was merged into Pulse subsequent to its acquisition and ceased to exist as a separate entity. Intercompany balances and transactions have been eliminated in consolidation.
Use Of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual amounts could differ from those estimates.
Concentration Of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and investments. The Company places its cash equivalents and investments with high credit quality financial institutions and, by policy, limits the amounts invested with any one financial institution or issuer. Deposits held with banks may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses since inception.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company believes the carrying amounts of its financial instruments, including cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses, approximate fair value due to the short-term nature of such instruments.
Cash, Cash Equivalents, And Marketable Investments	Cash, Cash Equivalents and Marketable Investments The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The Company has designated all marketable investments as available-for-sale and therefore, such marketable investments are reported at fair value, with unrealized gains and losses recognized in accumulated other comprehensive income (loss) (“OCI”) in stockholders’ equity. The cost of marketable securities is adjusted for the amortization of premiums and discounts to expected maturity. Premium and discount amortization is included in other income, net. Realized gains and losses, as well as interest income, on available-for-sale securities are also included in other income, net. The Company includes all of its available-for-sale securities in current assets. All of the Company’s marketable investments are subject to a periodic impairment review. The Company recognizes an impairment charge when a decline in the fair value of its marketable investments below the cost basis is judged to be other-than-temporary. Factors considered in determining whether a loss is temporary include the length of time and extent to which the marketable investments fair value has been less than the cost basis, the financial condition and near-term prospects of the investee, extent of the loss related to credit of the issuer, the expected cash flows from the security, the Company’s intent to sell the security and whether or not the Company will be required to sell the security before the recovery of its amortized cost. During the year ended December 31 2016, the Company did not recognize any impairment charges on its investments as it is more likely than not that the Company will recover their amortized cost basis upon sale or maturity. The Company did not hold investment securities at any time during the prior year.
Deferred and Capitalized Offering Costs	Deferred and Capitalized Offering Costs Costs incurred in connection with ongoing equity financing activities, consisting primarily of legal, accounting and other professional fees, are deferred until the related financing is either completed or abandoned. Costs related to completed equity financings are charged directly to additional paid-in capital. Costs related to abandoned financings are charged to operations.
Equipment	Equipment Equipment is recorded at cost and depreciated on a straight-line basis over their estimated useful lives, ranging from three to five years.
Intangible Assets	Intangible Assets The Company’s intangible assets consist of acquired patents and licenses, which are being amortized over their estimated useful lives of twelve years.
Long-Lived Assets	Long-Lived Assets The Company reviews long-lived assets, consisting of equipment and intangible assets, for impairment during each fiscal year or when events or changes in circumstances indicate the carrying value of these assets may exceed their current fair values. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the assets. Assets to be disposed of are separately presented in the consolidated balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated. The Company has not historically recorded any impairment to its long-lived assets. In the future, if events or market conditions affect the estimated fair value to the extent that a long-lived asset is impaired, the Company will adjust the carrying value of these long-lived assets in the period in which the impairment occurs. For the years ended December 31, 2016, 2015 and the period from May 19, 2014 (inception) through December 31, 2014, the Company had not deemed any long-lived assets as impaired, and was not aware of the existence of any indicators of impairment at such dates.
Goodwill	Goodwill The Company records goodwill when the consideration paid in a business acquisition exceeds the fair value of the net tangible assets and the identified intangible assets acquired. The Company reviews goodwill for impairment at least annually or whenever changes in circumstances indicate that the carrying value of the goodwill may not be recoverable. For the years ended December 31, 2016, 2015 and the period from May 19, 2014 (inception) through December 31, 2014, the Company had not deemed the value of goodwill as impaired, and was not aware of the existence of any indicators of impairment at such dates.
Stock-Based Compensation	Stock-Based Compensation The Company periodically issues stock options to officers, directors, employees and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date. Stock-based payments to officers, directors and employees, including grants of employee stock options, are recognized in the financial statements based on their grant date fair values. Stock option grants, which are generally time vested, are measured at the grant date fair value and charged to operations on a straight-line basis over the vesting period. The fair value of stock options is determined utilizing the Black-Scholes option-pricing model, which is affected by several variables, including the risk-free interest rate, the expected dividend yield, the life of the equity award, the exercise price of the stock option as compared to the fair value of the common stock on the grant date, and the estimated volatility of the common stock over the term of the equity award. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The Company estimates volatility based on the average historical volatilities of comparable public companies in a similar industry. The expected dividend yield is based on the current yield at the grant date; the Company has never declared or paid dividends and has no plans to do so for the foreseeable future. As permitted by Staff Accounting Bulletin No. 107, due to the Company’s lack of history and option activity, management utilizes the simplified method to estimate the expected term of options at the date of grant. Prior to the Company’s IPO, the fair value of common stock was determined by reference to either recent or anticipated cash transactions involving the sale of the Company’s common stock. Stock options issued to non-employees as compensation for services provided to the Company are accounted for based upon the estimated fair value of the stock option. Management utilizes the Black-Scholes option-pricing model to determine the fair value of the stock options issued by the Company. The Company recognizes this expense over the period in which the services are provided. The Company recognizes the fair value of stock-based compensation costs in general and administrative costs and in research and development costs, as appropriate, in the Company’s consolidated statements of operations. The Company issues new shares to satisfy stock option exercises.
Research Grants	Research Grants Research grants are generally funded and paid through governmental, institutional, educational or research organizations. Grants received from agencies of the federal government are subject to federal regulation as to how the Company conducts its research activities, and the Company is required to comply with the respective research agreement terms relating to those grants. Amounts received under research grants are nonrefundable, regardless of the success of the underlying research project, to the extent that such amounts are expended in accordance with the approved grant project. The Company is permitted to draw down the research grants after incurring the related expenses. Amounts received under research grants are offset against the related research and development costs in the Company’s consolidated statement of operations as the costs are incurred.
Research And Development Costs	Research and Development Costs Research and development costs consist primarily of compensation costs, fees paid to consultants and outside service providers and organizations (including research institutes at universities), development prototypes, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s product candidates. Research and development costs incurred by the Company are expensed as incurred, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different expensing schedule is more appropriate.
Patent Costs	Patent Costs The Company is the owner of numerous domestic and foreign patents. Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and any related patent applications, patent costs not related to acquired patents, including patent-related legal fees, filing fees and other costs, including internally generated costs, are expensed as incurred. During the years ended December 31, 2016 and 2015 patent costs totaled $0.5 million and $0.4 million, respectively. During the period from May 19, 2014 (inception) through December 31, 2014, patent costs were $26,000. Patent costs are included in research and development costs in the consolidated statements of operations and comprehensive loss.
Income Taxes	Income Taxes The Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities. The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company determines that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made. The Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company’s net operating losses have yet to be utilized, previous tax years remain open to examination by federal authorities and other jurisdictions in which the Company currently operates or has operated in the past. The Company is not currently under examination by any tax authority. The Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by U.S. GAAP. The tax effects of a position are recognized only if it is “more-likely-than-not” to be sustained by the taxing authority as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits of the position are recognized. At December 31, 2016 and 2015, the Company had not recorded any liability for uncertain tax positions. The Company includes interest and penalties related to uncertain tax positions as a component of income tax expense.
Comprehensive Loss	Comprehensive Loss Comprehensive loss consists of net loss and unrealized gains or losses on available-for-sale investments. The Company displays comprehensive loss and its components as part of the consolidated statements of operations and comprehensive loss.
Net Loss Per Share	Net Loss per Share The Company’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period. For purposes of this calculation, options to purchase common stock and common stock warrants are considered common stock equivalents. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted net loss per share. Basic and diluted net loss per common share is the same for all periods presented because all warrants and stock options outstanding are anti-dilutive. The following outstanding stock options and warrants to purchase common stock were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect:
Segment And Geographical Information	Segment and Geographical Information The Company operates and manages its business as one reportable and operating segment. The Company’s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. All of the Company’s long-lived assets are based in the United States.
Recently Adopted Standards	Segment and Geographical Information The Company operates and manages its business as one reportable and operating segment. The Company’s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. All of the Company’s long-lived assets are based in the United States. Recently Adopted Standards In August 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Updates (“ASU”) No. 2014-15, Presentation of Financial Statements – Going Concern Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern, which requires management to evaluate whether there are conditions or events that raise substantial doubt about an entity’s ability to continue as a going concern and to provide disclosures when certain criteria are met. The guidance is effective for annual periods beginning after December 15, 2016 and interim reporting periods starting in the first quarter of 2017. The Company adopted this standard as of December 31, 2016.
Recent Accounting Pronouncements	Recent Accounting Pronouncements During May 2014, the Financial Accounting Standards Board (“FASB”) issued (“ASU”) No. 2014-09, Revenue from Contracts with Customers. This updated standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective and permits the use of either the retrospective or cumulative effect transition method. In August 2015, the FASB issued an update to defer the effective date of this update by one year. This updated standard becomes effective for the Company in the first quarter of fiscal year 2018, but allows the Company to adopt the standard one year earlier if it so chooses. In March 2016, the FASB issued updates to this guidance to clarify the implementation guidance on principal versus agent considerations. In April 2016, the FASB issued guidance to clarify aspects related to identifying performance obligations and the licensing implementation guidance. In May 2016, the FASB issued guidance to clarify the implementation on narrow scope improvements and practical expedients. The Company is currently evaluating the impact of adopting these standards. During February 2016, the FASB issued ASU No. 2016-02, Leases, which amends the existing accounting standards for leases. The new standard requires lessees to record a right-of-use asset and a corresponding lease liability on the balance sheet (with the exception of short-term leases). For lessees, leases will continue to be classified as either operating or financing in the income statement. This ASU becomes effective for the Company in the first quarter of fiscal year 2019 and early adoption is permitted. This ASU is required to be applied with a modified retrospective approach and requires application of the new standard at the beginning of the earliest comparative period presented. The Company generally does not finance purchases of equipment or other capital, but does lease its facilities. While the Company is continuing to assess all potential impacts of this standard, it expects that most of its lease commitments will be subject to the updated standard and recognized as lease liabilities and right-of-use assets upon adoption. During March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-based Payment Accounting. This ASU simplifies the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. This ASU requires that excess tax benefits and deficiencies be recognized as income tax benefit or expense in the income statement. The Company currently plans to implement this ASU as required in the first quarter of fiscal year 2017. The Company does not expect the adoption of this ASU to have a significant impact on its financial position. During June 2016, the FASB issued ASU 2016-13, Financial Instruments — Measurement of Credit Losses on Financial Instruments, which requires measurement and recognition of expected credit losses for financial assets held. ASU 2016-13 is effective for the Company beginning January 1, 2020. The Company is currently evaluating the impact of adopting this standard. During January 2017, the FASB issued ASU 2017-04, Intangibles — Goodwill and Other (Topic 350): Simplifying the Accounting for Goodwill Impairment, which simplifies the accounting for goodwill impairment. This ASU removes Step 2 of the goodwill impairment test, which requires hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The new guidance also requires disclosure of the amount of goodwill at reporting units with zero or negative carrying amounts. ASU 2017-04 is effective for the Company beginning January 1, 2020. Early adoption is permitted for any impairment tests performed after January 1, 2017. The Company is currently evaluating the impact of adopting this standard.

Summary Of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2016

Summary Of Significant Accounting Policies [Abstract]

Anti-Dilutive Shares Excluded From Computation Of Diluted Net Loss Per Share



					May 19, 2014
					(inception)
	Years Ended				through
	December 31,				December 31,
	2016		2015		2014
Common stock warrants		874,610		299,625		299,625
Common stock options		1,229,355		875,221		—
Total		2,103,965		1,174,846		299,625

Fair Value Of Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2016

Fair Value Of Financial Instruments [Abstract]

Fair Value Of Financial Assets Measured On A Recurring Basis



		December 31, 2016
Assets	Classification		Level 1		Level 2		Level 3		Total
Money market funds	Cash and cash equivalents	$	1,726	$	—	$	—	$	1,726
Corporate bonds	Investments		—		13,289		—		13,289
Asset-backed security	Investments		—		1,017		—		1,017
Total assets measured at fair value		$	1,726	$	14,306	$	—	$	16,032

Equipment (Tables)

12 Months Ended

Dec. 31, 2016

Equipment [Abstract]

Equipment



	December 31,
	2016		2015
Laboratory equipment	$	425	$	356
Software		20		10
Furniture, fixtures and equipment		17		20
		462		386
Less: Accumulated depreciation		(145)		(57)
	$	317	$	329

Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2016

Intangible Assets [Abstract]

Schedule Of Intangible Assets



	December 31,
	2016		2015
Acquired patents and licenses	$	7,985	$	7,985
Less: Accumulated amortization		(1,442)		(777)
	$	6,543	$	7,208

Schedule Of Amortization Of Intangible Assets



Year Ending December 31:
2017	$	665
2018		666
2019		665
2020		666
2021		665
Thereafter		3,216
	$	6,543

Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2016

Accrued Expenses [Abstract]

Accrued Expenses



	December 31,
	2016		2015
Professional fees	$	285	$	84
Compensation expense		261		34
Other		205		40
Offering costs		—		240
	$	751	$	398

Stockholders' Equity And Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2016

Summary Of Stock Option Activity



				Weighted
		Weighted		Average
		Average		Remaining
	Number of	Exercise		Contractual
	Shares	Price		Life (in Years)
Stock options outstanding at December 31, 2015	875,221	$	3.51	7.8
Issued	405,132		4.44
Exercised	—		—
Expired/terminated	(50,998)		3.57
Stock options outstanding at December 31, 2016	1,229,355	$	3.82
Vested and expected to vest at December 31, 2016	1,229,355	$	3.82	7.6
Stock options exercisable at December 31, 2016	354,855	$	3.34	6.0

Summary Of Exercise Price Outstanding And Exercisable



Options Outstanding				Options Exercisable
		Weighted average
	Number	remaining contractual	Weighted average	Number	Weighted average
Exercise Price	outstanding	life (in years)	exercise price	vested	exercise price
$2.67	302,620	3.3	$ 2.67	176,528	$ 2.67
$4.00 - $4.28	692,335	8.9	4.02	178,327	4.00
$4.67 - $4.68	234,400	9.6	4.68	—	-
	1,229,355	7.6	$ 3.82	354,855	$ 3.34

Schedule Of Fair Value Of Employee Stock Options



					May 19, 2014
					(inception)
	Years Ended				through
	December 31,				December 31,
	2016		2015		2014
Expected term in years		6.08		3.5 - 6.25		—
Expected volatility		80%		89% - 90%		—
Risk-free interest rate		1.16%-1.45%		0.88% - 1.89%		—
Dividend yield		—		—		—

Total Stock-Based Compensation Expense



					May 19, 2014
					(inception)
	Years Ended				through
	December 31,				December 31,
	2016		2015		2014
General and administrative	$	674	$	397	$	—
Research and development		196		5		—
Total stock-based compensation expense	$	870	$	402	$	—

Common Stock Warrants [Member]

Summary Of Stock Option Activity



				Weighted
				Average
		Weighted		Remaining
	Number of	Average		Contractual
	Shares	Exercise Price		Life (in Years)
Warrants outstanding at December 31, 2015	299,625	$	2.67	5.85
Issued	574,985		5.00
Exercised	—		—
Expired/terminated	—		—
Warrants outstanding and exercisable at December 31, 2016	874,610	$	4.20	4.53

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2016

Income Taxes [Abstract]

Components Of Deferred Tax Assets



	December 31,
	2016		2015
Technology	$	(1,449)	$	(1,630)
Temporary differences		312		103
Credits		639		198
Net operating loss carryforwards		5,121		1,590
Total deferred tax assets		4,623		261
Valuation allowance		(4,623)		(261)
Net deferred tax assets	$	—	$	—

Reconcilement Of Tax Rates



					May 19, 2014
					(inception)
	Years Ended				through
	December 31,				December 31,
	2016		2015		2014
U.S. federal statutory tax rate	(35.0)	%	(35.0)	%	(35.0)	%
Valuation allowance	42.0	%	4.0	%	16.0	%
Permanent differences	2.0	%	1.0	%	15.0	%
State tax benefit and other	(9.0)	%	(7.0)	%	(4.0)	%
Effective tax rate	—	%	(37.0)	%	(8.0)	%

Reconciliation Of Unrecognized Tax Benefit Accounts


	December 31,
	2016		2015
Balance, January 1, 2016	$	66	$	—
Gross increases - tax positions in prior periods		—		—
Gross decreases - tax positions in prior periods		—		—
Gross increases - tax position in current period		147		66
Settlements		—		—
Lapses in statutes of limitations		—		—
Balance, December 31, 2016	$	213	$	66

Selected Quarterly Financial Data (Tables)

12 Months Ended

Dec. 31, 2016

Selected Quarterly Financial Data [Abstract]

Schedule Of Selected Quarterly Financial Data


	Quarter Ended
	2016								2015
	December 31,		September 30,		June 30,		March 31,		December 31,		September 30,		June 30,		March 31,
Revenue	$	—	$	—	$	—	$	—	$	—	$	—	$	—	$	—
Operating expenses:
General and administrative		870		893		642		528		417		408		243		156
Research and development		1,806		1,739		1,453		990		951		659		547		421
Amortization of intangible assets		167		166		166		166		167		167		166		166
Total operating expenses		2,843		2,798		2,261		1,684		1,535		1,234		956		743
Other income:
Interest income		34		31		3		—		—		—		—		—
Total other income		34		31		3		—		—		—		—		—
Loss from operations, before income taxes		(2,809)		(2,767)		(2,258)		(1,684)		(1,535)		(1,234)		(956)		(743)
Income tax benefit		—		—		—		—		(518)		(483)		(357)		(299)
Net loss		(2,809)		(2,767)		(2,258)		(1,684)		(1,017)		(751)		(599)		(444)
Other comprehensive loss:
Unrealized gain (loss) on available-for-sale securities, net of tax:		1		(8)		—		—		—		—		—		—
Comprehensive loss	$	(2,808)	$	(2,775)	$	(2,258)	$	(1,684)	$	(1,017)	$	(751)	$	(599)	$	(444)
Net loss per share
Basic and diluted net loss per share	$	(0.21)	$	(0.21)	$	(0.23)	$	(0.22)	$	(0.13)	$	(0.10)	$	(0.08)	$	(0.06)
Weighted average shares used to compute net loss per common share — basic and diluted		13,315		13,315		9,791		7,565		7,565		7,565		7,565		7,565

Organization and Business Operations (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended								7 Months Ended	12 Months Ended
	Jun. 21, 2016	May 23, 2016	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Subsidiary, Sale of Stock [Line Items]
Incorporation state												Nevada
Incorporation date												May 19, 2014
Proceeds from issuance of common stock from initial public offering, net of issuance costs	$ 20,300											$ 20,915
Net loss			$ (2,809)	$ (2,767)	$ (2,258)	$ (1,684)	$ (1,017)	$ (751)	$ (599)	$ (444)	$ (277)	$ (9,518)	$ (2,811)
Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock upon initial public offering, net of issuance costs, shares		5,000,000									1,125,000	5,750,000
Underwriters exercised overallotment option to purchase additional shares	749,846
Price per share	$ 4.00	$ 4.00
Net loss

Summary Of Significant Accounting Policies (Narrative) (Details) - USD ($)			7 Months Ended	12 Months Ended
	Dec. 31, 2014	May 19, 2014	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Summary Of Significant Accounting Policies [Line Items]
Impairment of investments				$ 0
Long-lived asset impairment	$ 0	$ 0		0	$ 0
Goodwill impairment	$ 0	$ 0		0	0
Patent related expenses			$ 26,000	500,000	400,000
Liability for uncertain tax positions				$ 0	$ 0
BEM and NB [Member]
Summary Of Significant Accounting Policies [Line Items]
Effective acquisition date				Nov. 06, 2014
TPI [Member]
Summary Of Significant Accounting Policies [Line Items]
Effective acquisition date				Nov. 06, 2014
Equipment [Member] \| Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Useful life				3 years
Equipment [Member] \| Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Useful life				5 years
Acquired Patents And Licenses [Member]
Summary Of Significant Accounting Policies [Line Items]
Intangible asset useful life				12 years

Summary Of Significant Accounting Policies (Anti-Dilutive Shares Excluded From Computation Of Diluted Net Loss Per Share) (Details) - shares	7 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	299,625	2,103,965	1,174,846
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	299,625	874,610	299,625
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total		1,229,355	875,221

Fair Value Of Financial Instruments (Fair Value Of Financial Assets Measured On Recurring Basis) (Details) $ in Millions	Dec. 31, 2016 USD ($)
ASSETS
Total assets measured at fair value	$ 16,032.0
Cash And Cash Equivalents [Member] \| Money Market Funds [Member]
ASSETS
Total cash and cash equivalents	1,726.0
Investments [Member] \| Corporate Bonds [Member]
ASSETS
Total investments	13,289.0
Investments [Member] \| Asset-Backed Securities [Member]
ASSETS
Total investments	1,017.0
Level 1 [Member]
ASSETS
Total assets measured at fair value	1,726.0
Level 1 [Member] \| Cash And Cash Equivalents [Member] \| Money Market Funds [Member]
ASSETS
Total cash and cash equivalents	1,726.0
Level 2 [Member]
ASSETS
Total assets measured at fair value	14,306.0
Level 2 [Member] \| Investments [Member] \| Corporate Bonds [Member]
ASSETS
Total investments	13,289.0
Level 2 [Member] \| Investments [Member] \| Asset-Backed Securities [Member]
ASSETS
Total investments	$ 1,017.0

Equipment (Details) - USD ($) $ in Thousands	7 Months Ended	12 Months Ended
Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Equipment, gross		$ 462	$ 386
Less: Accumulated depreciation		(145)	(57)
Equipment, net		317	329
Depreciation expense	$ 6	94	51
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Equipment, gross		425	356
Software [Member]
Property, Plant and Equipment [Line Items]
Equipment, gross		20	10
Furniture, Fixtures, And Equipment [Member]
Property, Plant and Equipment [Line Items]
Equipment, gross		$ 17	$ 20

Intangible Assets (Schedule Of Intangible Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Less: Accumulated amortization	$ (1,442)	$ (777)
Intangible assets, net	6,543	7,208
Acquired Patents And Licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	$ 7,985	$ 7,985

Intangible Assets (Schedule Of Amortization Of Intangible Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Intangible Assets [Abstract]
2017	$ 665
2018	666
2019	665
2020	666
2021	665
Thereafter	3,216
Intangible assets, net	$ 6,543	$ 7,208

Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Accrued Expenses [Abstract]
Professional fees	$ 285	$ 84
Compensation expense	261	34
Other	205	40
Offering costs		240
Accrued expenses	$ 751	$ 398

Stockholders' Equity And Stock-Based Compensation (Narrative) (Details) - USD ($)				1 Months Ended	7 Months Ended	12 Months Ended
	Feb. 07, 2017	May 23, 2016	Nov. 06, 2014	Nov. 30, 2014	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Oct. 05, 2016	Jun. 21, 2016	May 31, 2016	Jun. 30, 2015
Stockholders' Equity [Line Items]
Preferred Stock, shares authorized						5,000,000	5,000,000
Preferred Stock, par value						$ 0.001	$ 0.001
Preferred Stock, shares outstanding						0	0
Common stock, shares authorized						45,000,000	45,000,000
Common stock, par value						$ 0.001	$ 0.001
Common stock, shares issued				3,444,198		13,315,000	7,565,000
Common stock, shares outstanding						13,315,000	7,565,000
Proceeds from issuance of common stock					$ 8,000
Exercise price of warrants			$ 2.67
Exercisable period of warrants or rights					7 years
Value of warrants			$ 600,000
Aggregate issuance costs			$ 900,000
Exercise price						$ 3.34
Executive ownership percentage of diluted shares of common stock outstanding							3.00%
Aggregate intrinsic value exercisable options						$ 1,100,000
Fair value of options vested						1,200,000	$ 3,100,000
Stock-based compensation						870,000	402,000
Unrecognized compensation cost						$ 2,400,000
Weighted average remaining contractual life						2 years 10 months 2 days
MDB Capital Group, LLC [Member]
Stockholders' Equity [Line Items]
Proceeds from issuance of common stock						$ 8,000
Placement agent fee percentage			10.00%
Placement agent fees			$ 800,000
Legal fees and reimbursable expenses			54,000
General And Administrative [Member]
Stockholders' Equity [Line Items]
Stock-based compensation						674,000	397,000
Research And Development [Member]
Stockholders' Equity [Line Items]
Stock-based compensation						$ 196,000	$ 5,000
Stock Options [Member]
Stockholders' Equity [Line Items]
Exercise price						$ 3.34
Number of shares terminated						50,998
Stock Options [Member] \| 2015 Plan [Member]
Stockholders' Equity [Line Items]
Common stock, shares issued											1,134,818
Vesting period						4 years
Stock option grant, vest rate upon first anniversary						25.00%
Stock option grant, vest rate per quarter thereafter						8.33%
Stock Options [Member] \| 2015 Plan [Member] \| Maximum [Member]
Stockholders' Equity [Line Items]
Vesting period						10 years
Executive Amendment [Member]
Stockholders' Equity [Line Items]
Exercise price								$ 4.00
Initial Public Offering [Member]
Stockholders' Equity [Line Items]
Common stock, shares issued										5,749,846
Private Placement [Member]
Stockholders' Equity [Line Items]
Proceeds from issuance of common stock			$ 8,000,000
Price per share			$ 2.67
Offering consideration					$ 7,147,000
Private Placement [Member] \| Subsequent Event [Member]
Stockholders' Equity [Line Items]
Common stock, par value	$ 0.001
Proceeds from sale of stock to acquire business and intellectual property	$ 5,000,000
Underwriters [Member] \| Initial Public Offering [Member] \| Stock Options [Member]
Stockholders' Equity [Line Items]
Number of shares of common stock called by issuance of warrants, outstanding						574,985
Price per share						$ 5.00
Period the warrants are exercisable after issuance						180 days
Exercisable period of warrants or rights						5 years
Dividend yield						0.00%
Expected volatility						80.00%
Expected term						5 years
Underwriters [Member] \| Initial Public Offering [Member] \| Stock Options [Member] \| Minimum [Member]
Stockholders' Equity [Line Items]
Fair value of common stock per share						$ 4.12
Risk-free interest rate						1.22%
Underwriters [Member] \| Initial Public Offering [Member] \| Stock Options [Member] \| Maximum [Member]
Stockholders' Equity [Line Items]
Fair value of common stock per share						$ 4.27
Risk-free interest rate						1.38%
Common Stock Warrants [Member]
Stockholders' Equity [Line Items]
Exercisable period of warrants or rights						7 years
Number of shares terminated
Aggregate intrinsic value exercisable options						$ 2,000,000
Common Stock Warrants [Member] \| Private Placement [Member]
Stockholders' Equity [Line Items]
Shares sold			299,625
Common Stock [Member]
Stockholders' Equity [Line Items]
Common stock, shares outstanding					7,565,000	13,315,000	7,565,000
Shares sold		5,000,000			1,125,000	5,750,000
Proceeds from sale of stock to acquire business and intellectual property				$ 9,200,000
Price per share		$ 4.00							$ 4.00
Common Stock [Member] \| MDB Capital Group, LLC [Member]
Stockholders' Equity [Line Items]
Shares sold						1,125,000
Common Stock [Member] \| Executive Amendment [Member]
Stockholders' Equity [Line Items]
Optional shares to be granted							187,286
Common Stock [Member] \| Private Placement [Member]
Stockholders' Equity [Line Items]
Shares sold			2,996,253
Offering consideration					$ 3,000
MDB Capital Group, LLC [Member]
Stockholders' Equity [Line Items]
Exercise price of warrants					$ 2.67
Placement agent fees					$ 800,000
Offering consideration					$ 1,000
MDB Capital Group, LLC [Member] \| Initial Public Offering [Member]
Stockholders' Equity [Line Items]
Value of warrants						$ 1,400,000
MDB Capital Group, LLC [Member] \| Common Stock [Member]
Stockholders' Equity [Line Items]
Number of shares of common stock called by issuance of warrants, outstanding					299,625

Stockholders' Equity And Stock-Based Compensation (Summary Of Stock Warrant Activity) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted average remaining life	7 years 7 months 6 days
Common Stock Warrants [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Beginning Balance, Number of shares	299,625
Issued, Number of shares	574,985
Exercised, Number of shares
Expired/terminated, Number of shares
Ending Balance, Number of shares	874,610	299,625
Beginning Balance, Weighted average exercise price per share	$ 2.67
Issued, Weighted average exercise price per share	5.00
Exercised, Weighted average exercise price per share
Expired/terminated, Weighted average exercise price per share
Ending Balance, Weighted average exercise price per share	$ 4.20	$ 2.67
Weighted average remaining life	4 years 6 months 11 days	5 years 10 months 6 days

Stockholders' Equity And Stock-Based Compensation (Summary Of Stock Option Activity) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercisable, Weighted average exercise price per share	$ 3.34
Weighted average remaining life	7 years 7 months 6 days
Stock Options [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Beginning Balance, Number of shares	875,221
Issued, Number of shares	405,132
Exercised, Number of shares
Expired/terminated, Number of shares	(50,998)
Ending Balance, Number of shares	1,229,355	875,221
Vested and expected to vest, Number of shares	1,229,355
Exercisable, Number of shares	354,855
Beginning Balance, Weighted average exercise price per share	$ 3.51
Issued, Weighted average exercise price per share	4.44
Exercised, Weighted average exercise price per share
Expired/terminated, Weighted average exercise price per share	3.57
Ending Balance, Weighted average exercise price per share	3.82	$ 3.51
Vested and expected to vest, Weighted average exercise price per share	3.82
Exercisable, Weighted average exercise price per share	$ 3.34
Weighted average remaining life		7 years 9 months 18 days
Weighted average remaining life, Vested and expected to vest	7 years 7 months 6 days
Weighted average remaining life, exercisable	6 years
$2.67 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercisable, Weighted average exercise price per share	$ 2.67
Weighted average remaining life	3 years 3 months 18 days

Stockholders' Equity And Stock-Based Compensation (Summary Of Exercise Price Of Stock Options Outstanding And Exercisable) (Details)	12 Months Ended
	Dec. 31, 2016 $ / shares shares
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Number outstanding \| shares	1,229,355
Weighted average remaining contractual life (in years)	7 years 7 months 6 days
Weighted average exercise price	$ 3.82
Number vested \| shares	354,855
Weighted average exercise price	$ 3.34
$2.67 [Member]
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Number outstanding \| shares	302,620
Weighted average remaining contractual life (in years)	3 years 3 months 18 days
Weighted average exercise price	$ 2.67
Number vested \| shares	176,528
Weighted average exercise price	$ 2.67
$4.00 - $4.28 [Member]
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price, lower range	4.00
Exercise price, upper range	$ 4.28
Number outstanding \| shares	692,335
Weighted average remaining contractual life (in years)	8 years 10 months 24 days
Weighted average exercise price	$ 4.02
Number vested \| shares	178,327
Weighted average exercise price	$ 4.00
$4.67 - $4.68 [Member]
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price, lower range	4.67
Exercise price, upper range	$ 4.68
Number outstanding \| shares	234,400
Weighted average remaining contractual life (in years)	9 years 7 months 6 days
Weighted average exercise price	$ 4.68

Stockholders' Equity And Stock-Based Compensation (Schedule Of Fair Value Of Employee Stock Options) (Details) - Stock Options [Member]	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term in years	6 years 29 days
Expected volatility	80.00%
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term in years		3 years 6 months
Expected volatility		89.00%
Risk-free interest rate	1.16%	0.88%
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term in years		6 years 3 months
Expected volatility		90.00%
Risk-free interest rate	1.45%	1.89%

Stockholders' Equity And Stock-Based Compensation (Total Stock-Based Compensation Expense) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Total stock-based compensation expense	$ 870	$ 402
General And Administrative [Member]
Total stock-based compensation expense	674	397
Research And Development [Member]
Total stock-based compensation expense	$ 196	$ 5

Research Grants And Agreements (Details) $ in Thousands	3 Months Ended								7 Months Ended	12 Months Ended
Research Grants And Agreements (Details) $ in Thousands	Dec. 31, 2016 USD ($)	Sep. 30, 2016 USD ($)	Jun. 30, 2016 USD ($)	Mar. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2016 USD ($) item	Dec. 31, 2015 USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Number of additional grants \| item										0
Research and development expense	$ 1,806	$ 1,739	$ 1,453	$ 990	$ 951	$ 659	$ 547	$ 421	$ 26	$ 5,988	$ 2,578
BEM [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research grant funding									$ 200		300
ODURF [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Period of time for Sponsored Research Agreement ("SRA")										12 months
ODURF [Member] \| Sponsored Research Agreement ("SRA") [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development expense										$ 1,000	1,200
Incurred costs pursuant to various task orders										$ 900	$ 1,000

Income Taxes (Narrative) (Details) - USD ($)	3 Months Ended				7 Months Ended	12 Months Ended
Income Taxes (Narrative) (Details) - USD ($)	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	May 19, 2014
Income Taxes [Line Items]
Income tax provision (benefit)	$ 518,000	$ 483,000	$ 357,000	$ 299,000	$ 23,000		$ 1,657,000
Federal statutory tax rate					35.00%	35.00%	35.00%
Total unrecognized tax benefit	66,000					$ 213,000	$ 66,000
Accrued interest or penalties	$ 0				$ 0	$ 0	$ 0	$ 0
Federal And California [Member]
Income Taxes [Line Items]
Net operating loss carryforward, expiration						2032
Federal [Member]
Income Taxes [Line Items]
Net operating loss carryforwards						$ 11,700,000
Research and development credit carryforward						$ 400,000
Research and developmen tax credit carryforward, expiration						2035
California [Member]
Income Taxes [Line Items]
Net operating loss carryforwards						$ 11,500,000
Research and development credit carryforward						$ 400,000

Income Taxes (Components Of Deferred Tax Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Income Taxes [Abstract]
Technology	$ (1,449)	$ (1,630)
Temporary differences	312	103
Credits	639	198
Net operating loss carryforwards	5,121	1,590
Total deferred tax assets	4,623	261
Valuation allowance	(4,623)	(261)
Net deferred tax assets

Income Taxes (Reconcilement Of Tax Rates) (Details)	7 Months Ended	12 Months Ended
Income Taxes (Reconcilement Of Tax Rates) (Details)	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Income Taxes [Abstract]
U.S. federal statutory tax rate	(35.00%)	(35.00%)	(35.00%)
Valuation allowance	16.00%	42.00%	4.00%
Permanent differences	15.00%	2.00%	1.00%
State tax benefit and other	(4.00%)	(9.00%)	(7.00%)
Effective tax rate	(8.00%)		(37.00%)

Income Taxes (Reconciliation Of Unrecognized Tax Benefit Accounts) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Taxes [Abstract]
Unrecognized tax benefit, Beginning balance	$ 66
Increase in balance related to tax positions taken in prior year
Decrease in balance related to tax positions taken in prior year
Increase in balance related to tax positions taken during current year	147	66
Settlements
Lapses in statutes of limitations
Unrecognized tax benefit, Ending balance	$ 213	$ 66

Related Party Transactions (Details) $ / shares in Units, shares in Thousands	3 Months Ended								7 Months Ended	12 Months Ended		13 Months Ended
	Dec. 31, 2016 USD ($)	Sep. 30, 2016 USD ($)	Jun. 30, 2016 USD ($)	Mar. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2014 USD ($) $ / shares shares	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($) employee	Dec. 31, 2015 USD ($)	Nov. 06, 2014 USD ($) $ / shares
Related Party Transaction [Line Items]
Exercisable period of warrants or rights									7 years
Exercise price of warrants \| $ / shares													$ 2.67
Research and development	$ 1,806,000	$ 1,739,000	$ 1,453,000	$ 990,000	$ 951,000	$ 659,000	$ 547,000	$ 421,000	$ 26,000	$ 5,988,000	$ 2,578,000
Value of warrants													$ 600,000
Patent related expenses									26,000	500,000	400,000
Private Placement [Member]
Related Party Transaction [Line Items]
Offering consideration									7,147,000
MDB Capital Group, LLC [Member]
Related Party Transaction [Line Items]
Placement agent fees									800,000
Offering consideration									$ 1,000
Exercise price of warrants \| $ / shares									$ 2.67
Executive search expenses											$ 49,000
Number of directors appointed \| employee											1
Offering related expenses											$ 42,000
Patent related expenses											26,000
Accounts payable and accrued expenses					$ 58,000						58,000	$ 58,000
MDB Capital Group, LLC [Member] \| Initial Public Offering [Member]
Related Party Transaction [Line Items]
Underwriting discounts										1,800,000
Unaccountable expense reimbursement										200,000
Value of warrants	$ 1,400,000									$ 1,400,000
MDB Capital Group, LLC [Member] \| Chief Financial Officer [Member]
Related Party Transaction [Line Items]
Officers compensation, monthly												$ 4,000
Officer compensation									$ 8,000		$ 48,000
Common Stock [Member] \| Private Placement [Member]
Related Party Transaction [Line Items]
Shares sold \| shares									2,996
Offering consideration									$ 3,000

Commitments And Contingencies (Details)		7 Months Ended	12 Months Ended
Commitments And Contingencies (Details)	Feb. 07, 2017 shares	Dec. 31, 2014 USD ($) shares	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Jan. 31, 2017 ft²
Commitments and Contingencies [Line Items]
Lease expiration date			Mar. 31, 2017
Operating lease, monthly expense			$ 19,000
Rent expense, including common area maintenance charges		$ 19,000	$ 200,000	$ 200,000
Private Placement [Member]
Commitments and Contingencies [Line Items]
Offering consideration		$ 7,147,000
Private Placement [Member] \| Common Stock [Member]
Commitments and Contingencies [Line Items]
Shares sold \| shares		2,996,000
Offering consideration		$ 3,000
MDB Capital Group, LLC [Member]
Commitments and Contingencies [Line Items]
Offering consideration		$ 1,000
MDB Capital Group, LLC [Member] \| Common Stock [Member]
Commitments and Contingencies [Line Items]
Number of shares of common stock called by issuance of warrants, outstanding \| shares		299,625
Subsequent Event [Member]
Commitments and Contingencies [Line Items]
Area Of Lease \| ft²					15,697
Subsequent Event [Member] \| Private Placement [Member] \| Common Stock [Member]
Commitments and Contingencies [Line Items]
Shares sold \| shares	819,673

Employee Benefit Plans (Details) - USD ($)			12 Months Ended
Employee Benefit Plans (Details) - USD ($)	Dec. 31, 2014	May 19, 2014	Dec. 31, 2016	Dec. 31, 2015
Employee Benefit Plans [Abstract]
Employer matching contributions	$ 0	$ 0	$ 0	$ 0

Selected Quarterly Financial Data (Details) - USD ($) $ / shares in Units, shares in Thousands	3 Months Ended								7 Months Ended	12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Selected Quarterly Financial Data [Abstract]
Revenue
Operating expenses:
General and administrative	$ 870,000	$ 893,000	$ 642,000	$ 528,000	$ 417,000	$ 408,000	$ 243,000	$ 156,000	43,000	2,933,000	1,224,000
Research and development	1,806,000	1,739,000	1,453,000	990,000	951,000	659,000	547,000	421,000	26,000	5,988,000	2,578,000
Amortization of intangible assets	167,000	166,000	166,000	166,000	167,000	167,000	166,000	166,000	111,000	665,000	666,000
Costs of business acquisitions									120,000
Total operating expenses	2,843,000	2,798,000	2,261,000	1,684,000	1,535,000	1,234,000	956,000	743,000	300,000	9,586,000	4,468,000
Other income:
Interest income	34,000	31,000	3,000							68,000
Total other income	34,000	31,000	3,000							68,000
Loss from operations, before income taxes	(2,809,000)	(2,767,000)	(2,258,000)	(1,684,000)	(1,535,000)	(1,234,000)	(956,000)	(743,000)	(300,000)	(9,518,000)	(4,468,000)
Income tax benefit					(518,000)	(483,000)	(357,000)	(299,000)	(23,000)		(1,657,000)
Net loss	(2,809,000)	(2,767,000)	(2,258,000)	(1,684,000)	(1,017,000)	(751,000)	(599,000)	(444,000)	(277,000)	(9,518,000)	(2,811,000)
Other comprehensive loss:
Unrealized gain (loss) on available-for-sale securities, net of tax	1,000	(8,000)								(7,000)
Comprehensive loss	$ (2,808,000)	$ (2,775,000)	$ (2,258,000)	$ (1,684,000)	$ (1,017,000)	$ (751,000)	$ (599,000)	$ (444,000)	$ (277,000)	$ (9,525,000)	$ (2,811,000)
Net loss per common share - basic and diluted	$ (0.21)	$ (0.21)	$ (0.23)	$ (0.22)	$ (0.13)	$ (0.10)	$ (0.08)	$ (0.06)	$ (0.11)	$ (0.86)	$ (0.37)
Weighted average shares used to compute net loss per common share	13,315	13,315	9,791	7,565	7,565	7,565	7,565	7,565	2,511	11,009	7,565

Subsequent Events (Details)		1 Months Ended		7 Months Ended	12 Months Ended
Subsequent Events (Details)	Feb. 07, 2017 USD ($) $ / shares shares	Jan. 31, 2017 USD ($) ft²	Nov. 30, 2014 USD ($)	Dec. 31, 2014 USD ($) shares	Dec. 31, 2016 USD ($) $ / shares	Dec. 31, 2015 USD ($) $ / shares
Subsequent Event [Line Items]
Rent expense per month				$ 19,000	$ 200,000	$ 200,000
Lease obligations, less than one year					300,000
Lease obligations, one to three years					1,100,000
Lease obligations,three to five years					1,100,000
Lease obligations, more than five years					$ 300,000
Common stock, par value \| $ / shares					$ 0.001	$ 0.001
Common Stock [Member]
Subsequent Event [Line Items]
Gross proceeds			$ 9,200,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Area Of Lease \| ft²		15,697
Lease term		62 months
Security deposit		$ 101,000
Lease renewal term		5 years
Subsequent Event [Member] \| Landlord [Member]
Subsequent Event [Line Items]
Landlord obligatory improvement allowance per rentable square foot		$ 135.00
Subsequent Event [Member] \| Tier One Rent Expense First Two Months Of Lease Term [Member]
Subsequent Event [Line Items]
Rent expense per month		42,400
Subsequent Event [Member] \| Tier Two Rent Expense [Member]
Subsequent Event [Line Items]
Rent expense per month		$ 50,300
Private Placement [Member] \| Common Stock [Member]
Subsequent Event [Line Items]
Shares sold \| shares				2,996,000
Private Placement [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Common stock, par value \| $ / shares	$ 0.001
Price per share \| $ / shares	$ 6.10
Gross proceeds	$ 5,000,000
Private Placement [Member] \| Subsequent Event [Member] \| Common Stock [Member]
Subsequent Event [Line Items]
Shares sold \| shares	819,673

Label	Element	Value
Stock Issued During Period, Value, Issued for Services	us-gaap_StockIssuedDuringPeriodValueIssuedForServices	$ 3,785,000
Stock Issued During Period, Value, Acquisitions	us-gaap_StockIssuedDuringPeriodValueAcquisitions	5,411,000
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	8,000
Retained Earnings [Member]
Net Income Loss	us-gaap_NetIncomeLoss	(277,000)
Stock Issued During Period, Value, Issued for Services	us-gaap_StockIssuedDuringPeriodValueIssuedForServices
Stock Issued During Period, Value, Acquisitions	us-gaap_StockIssuedDuringPeriodValueAcquisitions
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues
Retained Earnings [Member] \| Private Placement [Member]
Sale of Stock, Consideration Received Per Transaction	us-gaap_SaleOfStockConsiderationReceivedPerTransaction
Accumulated Other Comprehensive Income [Member]
Net Income Loss	us-gaap_NetIncomeLoss
Stock Issued During Period, Value, Issued for Services	us-gaap_StockIssuedDuringPeriodValueIssuedForServices
Stock Issued During Period, Value, Acquisitions	us-gaap_StockIssuedDuringPeriodValueAcquisitions
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues
Accumulated Other Comprehensive Income [Member] \| Private Placement [Member]
Sale of Stock, Consideration Received Per Transaction	us-gaap_SaleOfStockConsiderationReceivedPerTransaction
Additional Paid In Capital [Member]
Net Income Loss	us-gaap_NetIncomeLoss
Stock Issued During Period, Value, Issued for Services	us-gaap_StockIssuedDuringPeriodValueIssuedForServices	3,783,000
Stock Issued During Period, Value, Acquisitions	us-gaap_StockIssuedDuringPeriodValueAcquisitions	5,409,000
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	7,000
Additional Paid In Capital [Member] \| Private Placement [Member]
Sale of Stock, Consideration Received Per Transaction	us-gaap_SaleOfStockConsiderationReceivedPerTransaction	7,144,000
Common Stock [Member]
Stock Issued During Period, Value, Issued for Services	us-gaap_StockIssuedDuringPeriodValueIssuedForServices	$ 2,000
Stock Issued During Period, Shares, Acquisitions	us-gaap_StockIssuedDuringPeriodSharesAcquisitions	2,027,000
Stock Issued During Period, Value, Acquisitions	us-gaap_StockIssuedDuringPeriodValueAcquisitions	$ 2,000
Stock Issued During Period, Shares, Issued for Services	us-gaap_StockIssuedDuringPeriodSharesIssuedForServices	1,417,000
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	$ 1,000

Fair Value Of Financial Instruments (Narrative) (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Fair Value Of Financial Instruments [Abstract]
Total liabilities measured at fair value	$ 0	$ 0